United Therapeutics Corporation Equity Securities, FV-NI, Unrealized Gain (Loss)
United Therapeutics Corporation (UTHR) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$48.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- United Therapeutics Corporation equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $13.40M.
- United Therapeutics Corporation equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$61.60M.
- United Therapeutics Corporation equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-06-30 was -$4.00M.
- United Therapeutics Corporation equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-03-31 was -$5.30M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2026-06-30 | $13.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$48.20M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$61.60M 10-Q · filed 2026-05-06 | |
| 2025-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$9.30M 10-Q · filed 2026-08-05 |
| 2025-03-31 | -$5.30M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |